english.prescrire.org > Prescrire International > N°245 - February 2023

n°245

February 2023

Issue Contents
Editorial

Free  Building the evidence base

p.31

Marketing Authorisations

Icosapent ethyl (Vazkepa°) in cardiovascular prevention

p.33-35
Uncertain reduction in cardiovascular mortality, and established, unjustified harms

Semaglutide (Wegovy°) and excess body weight

p.36-38
No proven efficacy against clinical complications as of late 2022

Inset. Is Ozempic° being used in obesity instead of diabetes?

p.37

Vosoritide (Voxzogo°) in achondroplasia

p.38

Roxadustat (Evrenzo°) in anaemia associated with chronic kidney disease

p.39
More dangerous than an injectable epoetin, with no greater efficacy

Prolonged-release aripiprazole for injection: a double dose now authorised at the start of treatment, but with no clinical evaluation

p.40

Cabozantinib (Cabometyx°) and nivolumab (Opdivo°) as first-line treatment for advanced kidney cancer

p.41-42

Cemiplimab (Libtayo°) as first-line monotherapy for certain lung cancers

p.42

Atezolizumab (Tecentriq°) as first-line monotherapy for certain lung cancers

p.42

Diroximel fumarate (Vumerity°) in relapsing-remitting multiple sclerosis

p.43-44

Luspatercept (Reblozyl°) in anaemia associated with beta-thalassaemia

p.44

Luspatercept (Reblozyl°) in anaemia associated with myelodysplastic syndrome

p.44

Bimekizumab (Bimzelx°) in plaque psoriasis

p.45

Osimertinib (Tagrisso°) as adjuvant treatment of certain lung cancers

p.45

Adverse Effects

Metformin during pregnancy: possible risk of malformations

p.46-48

Dorzolamide and brinzolamide as eye drops: Stevens-Johnson syndrome, toxic epidermal necrolysis and aplastic anaemia

p.48

Citalopram or escitalopram: sudden cardiac death

p.48

Vitamin D overdose in an adult: hypercalcaemia and renal failure

p.49

Common stem: -astine

p.49

Outlook

Free  Towards better patient care: drugs to avoid in 2023

p.50-53

Inset. Main changes in the 2023 update

p.52

Universities challenge the impact factor

p.53-54

Lobbying by the pharmaceutical industry in Brussels: at least 36 million euros per year

p.54

The 2025 workplan of the European coordination group for national drug regulatory agencies

p.55

Masthead

Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe